DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer-Reference-Cited by-同舟云学术

DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer

Published:2017-12-21 Issue:8 Volume:9 Page:7859-7866
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Cremolini Chiara¹,Del Re Marzia²,Antoniotti Carlotta¹,Lonardi Sara³,Bergamo Francesca³,Loupakis Fotios¹,Borelli Beatrice¹,Marmorino Federica¹,Citi Valentina²,Cortesi Enrico⁴,Moretto Roberto¹,Ronzoni Monica⁵,Tomasello Gianluca⁶,Zaniboni Alberto⁷,Racca Patrizia⁸,Buonadonna Angela⁹,Allegrini Giacomo¹⁰,Ricci Vincenzo¹¹,Di Donato Samantha¹²,Zagonel Vittorina³,Boni Luca¹³,Falcone Alfredo¹,Danesi Romano²

Affiliation:

1. Unit of Medical Oncology 2, Azienda Ospedaliera-Universitaria Pisana, University of Pisa, Istituto Toscano Tumori, Pisa, Italy

2. Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

3. Oncologia Medica 1, Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padova, Italy

4. Department of Medical Oncology, Policlinico Umberto I “Sapienza” University of Rome, Roma, Italy

5. Medical Oncology Unit, Ospedale San Raffaele-IRCCS, Milano, Italy

6. ASST di Cremona, Ospedale di Cremona, Cremona, Italy

7. Fondazione Poliambulanza Hospital, Brescia, Italy

8. SSD ColoRectal Unit-Dipartimento di Oncologia, AOU Città della Salute e della Scienza di Torino, Torino, Italy

9. Medical Oncology Unit, CRO-National Cancer Institute, Aviano, Italy

10. Medical Oncology Unit, Presidio Ospedaliero Felice Lotti, Pontedera, Italy

11. Department of Oncology, S. Croce and Carle Teaching Hospital, Cuneo, Italy

12. Medical Oncology Department, Nuovo Ospedale-Santo Stefano, Istituto Toscano Tumori, Prato, Italy

13. Clinical Trial Coordinating Center, AOU Careggi, Istituto Toscano Tumori, Firenze, Italy

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genotyping of <i>UGT1A1</i> and <i>DPYD</i> polymorphisms in patients with colorectal cancer. A review;Journal of Modern Oncology;2024-02-21

2. Upfront DPYD Genotype-Guided Treatment for Fluoropyrimidine-Based Chemotherapy in Advanced and Metastatic Colorectal Cancer: A Cost-Effectiveness Analysis;Value in Health Regional Issues;2023-09

3. Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI): Study Protocol for a Pragmatic Implementation Trial for Establishing DPYD and UGT1A1 Screening to Guide Chemotherapy Dosing;Frontiers in Oncology;2022-07-05

4. Risk Factors for Infections, Antibiotic Therapy, and Its Impact on Cancer Therapy Outcomes for Patients with Solid Tumors;Life;2021-12-11

5. Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO;ESMO Open;2021-12